Consistent with these data, pharmacological PARP-inhibition on H2O2-induced endothelial dysfunction supports the notion that PARP inhibition may represent a potential therapeutic approach to reduce vascular dysfunction induced by oxidative stress [52]. The gene discussed is PARP1; the disease is endothelial dysfunction.